Cupid shares rally 64% in a week, hit new all-time high of Rs 152. Should you book profits?
Cupid Ltd
rallied 63.7% over the past week to hit a fresh all-time high of Rs 152 on the BSE today, driven by strong technical momentum and rising volumes. The sharp uptrend comes amid consistent buying interest, supported by bullish technical indicators.
Around 10:30 am on Monday, the stock's total traded quantity stood at 6.36 lakh shares, with a turnover of Rs 9.66 crore. The company's market capitalization was at Rs 3,948.84 crore.
Explore courses from Top Institutes in
Select a Course Category
Data Science
Public Policy
others
MBA
Project Management
healthcare
Product Management
PGDM
Finance
Data Analytics
Degree
Cybersecurity
Data Science
Healthcare
Others
Digital Marketing
Management
Artificial Intelligence
Operations Management
Leadership
Technology
CXO
Design Thinking
MCA
Skills you'll gain:
Duration:
10 Months
IIM Kozhikode
CERT-IIMK DABS India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
30 Weeks
IIM Kozhikode
SEPO - IIMK-AI for Senior Executives India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
30 Weeks
IIM Kozhikode
SEPO - IIMK-AI for Senior Executives India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
11 Months
E&ICT Academy, Indian Institute of Technology Guwahati
CERT-IITG Postgraduate Cert in AI and ML India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
11 Months
IIT Madras
CERT-IITM Advanced Cert Prog in AI and ML India
Starts on
undefined
Get Details
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Algeria Solar Panels: See How Much It Will Cost To Install Them (See Prices)
Solar Panel | Search Ads
Learn More
Undo
On Saturday, the company also informed that
Aditya Kumar Halwasiya
, Chairman and Managing Director of Cupid Ltd, featured in Avendus Wealth - Hurun lndia U30 List 2025.
'Cupid Limited, (BSE – 530843, NSE – CUPID), is delighted to announce that its Chairman & Managing Director, Mr. Aditya Kumar Halwasiya, has been named to the Avendus Wealth – Hurun
India U30 List 2025
. This prestigious accolade recognizes India's most dynamic young leaders under 30 who are driving innovation, transformation, and sustainable growth in their respective fields,' the company's filing to the stock exchanges stated.
After this sharp rally, how do analysts recommend trading the stock?
Live Events
According to Sudeep Shah, Deputy Vice President and Head of Technical & Derivatives Research at SBI Securities, 'The price has moved up sharply, having risen nearly 34% in just the last 6 trading sessions. The strong move in the price was supported by a rise in volumes as well.'
He added that the stock is trading above its key short and term long moving averages and the momentum indicators and oscillators are also reinforcing the bullish strength.
Shah noted that Rs 115 is likely to act as a strong support level for the stock, while a follow-up move from current levels could push the price towards Rs 180, followed by Rs 200 levels in the short term.
Meanwhile, Hardik Matalia, Derivative Analyst at Choice Broking, observed that the shares of Cupid are currently trading around Rs 146.77, hovering at record high levels after delivering a remarkable rally of nearly 165% from its April 2025 lows.
He noted that the stock has been consistently forming higher highs and higher lows on the daily timeframe, reinforcing its strong bullish structure.
However, Matalia highlighted that with the Relative Strength Index (RSI) at 85.86, the stock is now firmly in the overbought territory, indicating the possibility of an impending time-wise or price-wise correction in the near term.
He further pointed out that the stock is trading well above all its key short-term and long-term moving averages, underlining the prevailing strong momentum, but cautioned that such steep rallies often invite consolidation or retracement, especially when momentum indicators are overheated.
For short-term traders, Matalia suggested it 'would be prudent to book profits at current levels and consider re-entering on meaningful dips near support zones, once signs of stability or reversal emerge.'
He also advised long-term investors already holding the stock to 'consider booking partial profits to lock in gains,' while monitoring for any healthy retracement, which could present an opportunity to accumulate further in a staggered manner.
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
13 minutes ago
- Business Standard
Gujarat remains top exporting state in FY25 with ₹9.83 trn exports: FIEO
Gujarat retained its position as India's top exporting state in 2024-25, with outbound shipments worth Rs 9.83 lakh crore, accounting for 26.6 per cent of the country's total exports, FIEO said on Tuesday. It said despite a marginal dip from the previous year, Gujarat's exports remained significantly ahead of all other states, nearly Rs 4.3 lakh crore more than Maharashtra (Rs 5,57,271 crore), the second-ranked state. Maharashtra is followed by Tamil Nadu, Karnataka, Uttar Pradesh, Andhra Pradesh and Telangana, according to the analysis of the Federation of Indian Export Organisations (FIEO). "In 2024-25, Gujarat reaffirmed its leadership as India's top exporting state, accounting for Rs 9.83 lakh crore, which is 26.6 per cent of the country's total exports," it said. It added that Gujarat's export dominance continues to be driven by a few high-performing districts, with Jamnagar maintaining a commanding lead at Rs 3.63 lakh crore, largely owing to its petroleum and refinery exports. Jamnagar contributes over one-third of the state's total. The top five export commodities from the state are Petroleum Products, Gems and Jewellery, Organic Chemicals, Pharmaceuticals, and Engineering Goods (Machinery). In 2024-25, Uttar Pradesh contributes Rs 1.86 lakh crore to India's total exports of Rs 37.02 lakh crore. This accounts for 5 per cent of the country's total exports, positioning Uttar Pradesh as an important player in India's export landscape. "Uttar Pradesh has demonstrated a commendable diversification in its export markets, reaching both traditional and emerging economies across continents," it said, adding that the US continues to be the top export destination of the state.
&w=3840&q=100)
Business Standard
13 minutes ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
Economic Times
13 minutes ago
- Economic Times
Britannia Q1 profit dips 0.8% YoY; revenue up 8.8%, misses estimates
Biscuit major Britannia Industries Ltd reported a marginal 0.8% year-on-year (yoy) drop in standalone net profit at Rs 498.27 crore for the first quarter ending June 30th, while standalone revenue from operations grew 8.8% YoY at Rs 4,452.74 crore. The performance during the quarter missed street estimates. ADVERTISEMENT The company did not attribute any reason behind the fall in profit. Britannia's managing director Varun Berry said in the earnings release that there was a marginal uptick in consumption across both urban and rural markets in the quarter under review, underpinned by moderating inflation which helped (near) double-digit growth after the last few periods. Berry said as the year progresses, the company's focus will remain on sustaining a healthy growth trajectory while protecting margins amidst a heightened competitive landscape across product categories. "We aim to further reinforce our market leadership through continued investments in brand building and innovations," he said. Britannia's consolidated revenue from operations for the quarter went up by 8.8% yoy at Rs 4,622.22 crore while net profit grew by 3% yoy at Rs 520.13 crore. Consolidated sales for the quarter grew 9.8% at Rs 4,535 said the company had a robust double-digit growth across our focus markets and in adjacent bakery categories such as rusk, wafers and croissant. He said the company's performance during the quarter underscores the effectiveness of its focused execution strategy -- maximizing value from existing outlets, more agile servicing to key stores, and driving operational efficiencies across distribution networks. ADVERTISEMENT On Tuesday, Britannia's shares closed 2.66% down on the BSE at Rs 5,631.35 a piece. The results were declared after market hours. The company in a stock market notice said the board of directors authorized chairman Nusli N. Wadia to sign the results which were submitted to the stock exchanges. (You can now subscribe to our ETMarkets WhatsApp channel)
